This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Read Dan on Real Money
By This Author:
« Back
Page 1 of 2

Buying Bluebird's Blockbuster Potential at a Discount

By Dan Rosenblum

It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.

10:33AM 07/17/14

Why I'm More Confident in Sarepta Than Ever Before

By Dan Rosenblum

Biotech trader Dan Rosenblum believes the recent selloff in Sarepta is a tremendous buying opportunity.

10:06AM 11/04/13

Sarepta: Staying Long and Strong

By Dan Rosenblum

Contributor Dan Rosenblum believes Sarepta's upside potential far outweighs the risk in the stock.

09:25AM 04/25/13

Sarepta Is Undervalued Even Without Eteplirsen Accelerated Approval

By Dan Rosenblum

The exon-skipping drug technology is worth a lot more than just eteplirsen alone.

10:39AM 03/05/13

Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

By Dan Rosenblum

Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.

07:30AM 12/20/12

Still Bullish on BioMarin, Lexicon Pharma

By Dan Rosenblum

TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.

11:28AM 11/07/12

Sunshine Heart: A Promising Treatment for Heart Failure Patients

By Dan Rosenblum

Sunshine's C-Pulse is a heart-assist device for patients who fall between the cracks of current therapy.

08:00AM 11/05/12

Lexicon Pharma: Blockbuster Potential From A Diabetes Drug

By Dan Rosenblum

Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.

06:10AM 10/16/12

Biomarin: Four Clinical Trial Events to Watch Before Year End

By Dan Rosenblum

TheStreet contributor Dan Rosenblum explains why Biomarin is a very busy biotech.

07:03AM 09/25/12

Nanosphere: A Low-Risk, High-Growth Diagnostic Stock

By Dan Rosenblum

A hospital-based sepsis test is the launching pad for Nanosphere.

07:13AM 09/18/12

« Back
Page 1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs